Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | musashi | 0.0033 | 0.3537 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 1 | 1 |
Brugia malayi | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 0.3537 | 0.6116 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.5545 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.5545 | 0.5545 |
Brugia malayi | calcium-independent alpha-latrotoxin receptor 2, putative | 0.0019 | 0.0375 | 0.0375 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 0.3537 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 1 | 1 |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 0.3537 | 0.3537 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 0.3537 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.5545 | 0.5545 |
Brugia malayi | Latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Schistosoma mansoni | lamin | 0.0033 | 0.3537 | 0.6116 |
Echinococcus granulosus | lamin | 0.0033 | 0.3537 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 1 | 1 |
Echinococcus multilocularis | lamin | 0.0033 | 0.3537 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.3397 | 0.3397 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 0.3537 | 1 |
Onchocerca volvulus | 0.0033 | 0.3537 | 0.5 | |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | latrophilin receptor protein 2 | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | hypothetical protein | 0.0019 | 0.0375 | 0.0375 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 0.3537 | 0.3537 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 0.3537 | 0.3537 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.5623 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 5.6234 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.